Literature DB >> 11888723

When midazolam fails.

Christine Cheng1, Célia Roemer-Becuwe, Jose Pereira.   

Abstract

Significant distress is experienced by patients, families, and caregivers when a symptom or disorder, such as an agitated delirium, becomes an intractable, or a catastrophic event, such as irreversible stridor. When palliative sedation is indicated for these patients, midazolam is usually the preferred drug. In some cases, however, midazolam fails to provide adequate sedation. Two cases are presented to illustrate this phenomenon and explore the possible mechanisms underlying this lack of response. These mechanisms appear to be multifaceted. The heterogeneity of the GABA(A) receptor complex and the alterations that this complex can undergo functionally can explain, to some degree, the diversity of the physiological and pharmacological outcomes. Other factors responsible for the diversity in response may include concomitant medications, age, concurrent disease, overall health status, alcohol use, liver disease, renal disease, smoking and hormonal status. Evidence-based guidelines on alternative treatment options should midazolam fail are required. In the interim, a lower threshold for adding an alternative drug, such as phenobarbital, or substituting midazolam with another drug, such as propofol, should be considered in these circumstances.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888723     DOI: 10.1016/s0885-3924(01)00412-2

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  9 in total

1.  Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study.

Authors:  Giampiero Porzio; Federica Aielli; Lucilla Verna; Giovanna Micolucci; Paolo Aloisi; Corrado Ficorella
Journal:  Support Care Cancer       Date:  2009-04-03       Impact factor: 3.603

2.  Delirium during intravenous sedation with midazolam alone and with propofol in dental treatment.

Authors:  Y Mohri-Ikuzawa; H Inada; N Takahashi; H Kohase; S Jinno; M Umino
Journal:  Anesth Prog       Date:  2006

3.  Practice and documentation of palliative sedation: a quality improvement initiative.

Authors:  M McKinnon; C Azevedo; S H Bush; P Lawlor; J Pereira
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

4.  Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center.

Authors:  Ahmed Elsayem; Eardie Curry Iii; Jeanette Boohene; Mark F Munsell; Bianca Calderon; Frank Hung; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2008-05-07       Impact factor: 3.603

Review 5.  Palliative Sedation for the Terminally Ill Patient.

Authors:  Ferdinando Garetto; Ferdinando Cancelli; Romina Rossi; Marco Maltoni
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

6.  Phenobarbital but Not Diazepam Reduces AMPA/kainate Receptor Mediated Currents and Exerts Opposite Actions on Initial Seizures in the Neonatal Rat Hippocampus.

Authors:  Romain Nardou; Sumii Yamamoto; Asma Bhar; Nail Burnashev; Yehezkel Ben-Ari; Ilgam Khalilov
Journal:  Front Cell Neurosci       Date:  2011-07-28       Impact factor: 5.505

7.  Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control.

Authors:  Vincent Gamblin; Vincent Berry; Emmanuelle Tresch-Bruneel; Michel Reich; Arlette Da Silva; Stéphanie Villet; Nicolas Penel; Chloé Prod'Homme
Journal:  BMC Palliat Care       Date:  2020-06-19       Impact factor: 3.234

Review 8.  Sedation level with midazolam: A pediatric surgery approach.

Authors:  Carmen Flores-Pérez; Luis Alfonso Moreno-Rocha; Juan Luis Chávez-Pacheco; Norma Angélica Noguez-Méndez; Janett Flores-Pérez; María Fernanda Alcántara-Morales; Luz Cortés-Vásquez; Lina Sarmiento-Argüello
Journal:  Saudi Pharm J       Date:  2022-05-23       Impact factor: 4.562

9.  Anticipation of distress after discontinuation of mechanical ventilation in the ICU at the end of life.

Authors:  E J O Kompanje; B van der Hoven; J Bakker
Journal:  Intensive Care Med       Date:  2008-05-31       Impact factor: 17.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.